As a child I remember hearing the saying that "Silence is Golden..." So while many here take it as a bad thing at the moment, I do not... I think it may lead to something better when the time becomes appropriate. There is likely a reason for it at the moment and I trust the motivations of the management team so I think it is a positive and not a negative...
And amid the silence there are concrete positive signs:
1. JDRF Booths, the very first step in the development of the MannKind partnership with the JDRF
2. Mike's tweet that he is not worried
3. NRx numbers are the highest they have been since May I believe (based on my memory of seeing Liane's chart, although I could be off a few weeks either way)
4. Epi development was ahead of the curve and makes MannKind even more relevant in the world of Pharma given the current discussions on pricing of Epi pens
5. Use of Laura Kronen in marketing, where was Sanofi's relationship with real world users?
6. Minitaka partnership that was recently acknowledged in their video posted on this site
7. RSL, even though we have yet to hear details, we have been told to expect, albeit likely nominal, a milestone payment from them in 4th Q 16'
8. Mike investing his own money and Matt too to buy more shares after it appeared as a concern on this board. And you think they don't listen? Seriously why should they buy shares on the open market when they get options?
9. Listing on the TASE
And the above list does not include:
1. New sales force from scratch
2. Hiring of Nurse Practitioners
3. New Web site
4. MannKind Cares
5. Manufacturing change over
6. Titration paks
Other more speculative opportunities that may or may not happen sooner than later:
1. Settlement with Sanofi
2. Epi partnership
3. Jump in weekly scripts
4. Label Change
5. Official start of pediatric studies
To me this is all positive, some more speculative than others but all good and certainly not reflective of the current share price. I will buy more (my personal opinion not offered as advice) as soon as the money situation is sorted out. I believe as I have said before that I do not think dilution at this point (subject to terms but recognizing/accepting of current financial situation the terms will not be in our favor as if s/p were higher) that dilution is a bad thing. Some dilution has imo been priced in while the rest of the decline in s/p, if and when dilution happens, will drive the price down more in the short term but when people/investors realize it has taken finances off the table as an issue (assuming we get 12 months worth of cash burn) then I think the price will begin to come back up especially in light of the above, and that's when I will start to buy.
I get that people are handling this in different ways... And everyone has a different level of involvement, tolerance and own need/reason for doing what they do on this board. Some are pure and simple or straight forward, others are less so to varying degrees...
I have been a shareholder since 2009 and I am not stressed nor angry. As who would I get angry at? Myself I guess, as I am the only one to blame for my decisions. Every decision I have made so far regarding MannKind has been under my control. I could of sold when it hit $11.48 the night of the FDA Ad Com Vote but I chose not too. Could have sold anytime since but have chose not too. Hindsight is a beautiful thing when you are right...
I continue to believe in the science, I continue to believe that Matt, Mike, et al.. are doing a very good job under the circumstances... And I continue to believe that Al Mann's legacy, the health of diabetics and my personal investment in time, effort and capital are worth it even if not reflected in the current share price.
Need to no if i should get the good stuff or generic.. lol